Carbohydrate-based cancer vaccines: Target cancer with sugar bullets

Glycoconjugate Journal

Volumn 29, Issue 5-6, 2012, Pages 259-271

  Liu, Chang Cheng ^a   Ye, Xin Shan ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Antigen.; Carbohydrate based anti cancer vaccine.; Carrier; Immune tolerance.; Immunotherapy.

Indexed keywords

AMPHOLYTE; CANCER VACCINE; CARBOHYDRATE ANTIGEN; EPITOPE; GANGLIOSIDE GD3; GANGLIOSIDE GM2; KEYHOLE LIMPET HEMOCYANIN; MANNAN; MUCIN 1; PHOSPHORYL LIPID A; POLYSIALIC ACID; QS 21; SYNTHETIC PEPTIDE; THERATOPE; TUMOR ANTIGEN;

ANTIBODY TITER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CROSS REACTION; CYTOKINE RELEASE; DISTANT METASTASIS; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LUNG SMALL CELL CANCER; MELANOMA; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CROSS LINKING; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CANCER VACCINES; CARBOHYDRATE SEQUENCE; CARBOHYDRATES; HUMANS; IMMUNE TOLERANCE; IMMUNOCONJUGATES; IMMUNOTHERAPY; MICE; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84865742289     PISSN: 02820080     EISSN: 15734986     Source Type: Journal    
DOI: 10.1007/s10719-012-9399-9     Document Type: Article

References (151)

1. Coley, W.B.: The treatment of malignat tumors by repeated inoculations of erysipelas: With a report of ten original cases. Am. J. Med. Sci. 105, 487-510 (1893
2. Dougan, M., Dranoff, G.: Immune therapy for cancer. Annu. Rev. Immunol. 27, 83-117 (2009
3. Buonaguro, L., Petrizzo, A., Tornesello, M.L., Buonaguro, F.M.: Translating tumor antigens into cancer vaccines. Clin. Vaccine Immunol. 18, 23-34 (2011
4. Chiang, C.L., Kandalaft, L.E., Coukos, G.: Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int. Rev. Immunol. 30, 150-182 (2011
5. Dranoff, G.: GM-CSF-based cancer vaccines. Immunol. Rev. 188, 147-154 (2002 (Pubitemid 35398872)
6. Jinushi, M., Hodi, F.S., Dranoff, G.: Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factorsecreting tumor cell vaccines. Immunol. Rev. 222, 287-298 (2008 (Pubitemid 351430380)
7. Emens, L.A.: GM-CSF-secreting vaccines for solid tumors. Curr. Opin. Investig. Drugs 10, 1315-1324 (2009
8. Harris, J.E., Ryan, L., Hoover Jr., H.C., Stuart, R.K., Oken, M.M., Benson 3rd, A.B., Mansour, E., Haller, D.G., Manola, J., Hanna Jr., M.G.: Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J. Clin. Oncol. 18, 148-157 (2000 (Pubitemid 30036348)
9. Berd, D., Sato, T., Maguire Jr., H.C., Kairys, J., Mastrangelo, M.J.: Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J. Clin. Oncol. 22, 403-415 (2004 (Pubitemid 41079768)
10. De Gruijl, T.D., van den Eertwegh, A.J., Pinedo, H.M., Scheper, R.J.: Whole-cell cancer vaccination: From autologous to allogeneic tumor- And dendritic cell-based vaccines. Cancer Immunol. Immunother. 57, 1569-1577 (2008
11. Lesterhuis,W.J., Aarntzen, E.H., De Vries, I.J., Schuurhuis, D.H., Figdor, C.G., Adema, G.J., Punt, C.J.: Dendritic cell vaccines in melanoma: From promise to proof? Crit. Rev. Oncol. Hematol. 66, 118-134 (2008
12. Higano, C.S., Schellhammer, P.F., Small, E.J., Burch, P.A., Nemunaitis, J.,Yuh, L., Provost,N., Frohlich,M.W.: Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115, 3670-3679 (2009
13. Murshid, A., Gong, J., Calderwood, S.K.: Heat-shock proteins in cancer vaccines: Agents of antigen cross-presentation. Expert Rev. Vaccines 7, 1019-1030 (2008
14. Xie, J., Zhu, H., Guo, L., Ruan, Y., Wang, L., Sun, L., Zhou, L., Wu, W., Yun, X., Shen, A., Gu, J.: Lectin-like oxidized lowdensity lipoprotein receptor-1 delivers heat shock protein 60- fused antigen into the MHC class I presentation pathway. J. Immunol. 185, 2306-2313 (2010
15. Mazzaferro, V., Coppa, J., Carrabba, M.G., Rivoltini, L., Schiavo, M., Regalia, E., Mariani, L., Camerini, T., Marchiano, A., Andreola, S., Camerini, R., Corsi, M., Lewis, J.J., Srivastava, P.K., Parmiani, G.: Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res. 9, 3235-3245 (2003 (Pubitemid 37082717)
16. Testori, A., Richards, J., Whitman, E., Mann, G.B., Lutzky, J., Camacho, L., Parmiani, G., Tosti, G., Kirkwood, J.M., Hoos, A., Yuh, L., Gupta, R., Srivastava, P.K.: Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 study group. J. Clin. Oncol. 26, 955-962 (2008 (Pubitemid 351398090)
17. Wood, C., Srivastava, P., Bukowski, R., Lacombe, L., Gorelov, A.I., Gorelov, S., Mulders, P., Zielinski, H., Hoos, A., Teofilovici, F., Isakov, L., Flanigan, R., Figlin, R., Gupta, R., Escudier, B.: An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, openlabel, randomised phase III trial. Lancet 372, 145-154 (2008
18. Dalgleish, A., Pandha, H.: Tumor antigens as surrogate markers and targets for therapy and vaccines. Adv. Cancer Res. 96, 175- 190 (2007
19. Caspi, R.R.: Immunotherapy of autoimmunity and cancer: The penalty for success. Nat. Rev. Immunol. 8, 970-976 (2008
20. Dalgleish, A.G.: Therapeutic cancer vaccines: Why so few randomised phase III studies reflect the initial optimism of phase II studies. Vaccine 29, 8501-8505 (2011
21. Ragupathi, G.: Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol. Immunother. 43, 152- 157 (1996 (Pubitemid 26417595)
22. Sanders, D.S., Kerr, M.A.: Lewis blood group and CEA related antigens; coexpressed cell-cell adhesion molecules with roles in the biological progression and dissemination of tumours. Mol. Pathol. 52, 174-178 (1999 (Pubitemid 29369201)
23. Dennis, J.W., Granovsky, M., Warren, C.E.: Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta 1473, 21-34 (1999
24. Hakomori, S.: Tumor-associated carbohydrate antigens defining tumor malignancy: Basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 491, 369-402 (2001 (Pubitemid 32595136)
25. Werther, J.L., Tatematsu, M., Klein, R., Kurihara, M., Kumagai, K., Llorens, P., Guidugli Neto, J., Bodian, C., Pertsemlidis, D., Yamachika, T., Kitou, T., Itzkowitz, S.: Sialosyl-Tn antigen as a marker of gastric cancer progression: An international study. Int. J. Cancer 69, 193-199 (1996 (Pubitemid 26233298)
26. Kobata, A., Amano, J.: Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol. Cell Biol. 83, 429-439 (2005 (Pubitemid 41044621)
27. Cazet, A., Julien, S., Bobowski, M., Burchell, J., Delannoy, P.: Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Res. 12, 204 (2010
28. Heimburg-Molinaro, J., Lum, M., Vijay, G., Jain, M., Almogren, A., Rittenhouse-Olson, K.: Cancer vaccines and carbohydrate epitopes. Vaccine 29, 8802-8826 (2011
29. Komminoth, P., Roth, J., Lackie, P.M., Bitter-Suermann, D., Heitz, P.U.: Polysialic acid of the neural cell adhesion molecule distinguishes small cell lung carcinoma from carcinoids. Am. J. Pathol. 139, 297-304 (1991
30. Dennis, J.W.: N-linked oligosaccharide processing and tumor cell biology. Semin. Cancer Biol. 2, 411-420 (1991
31. Fernandes, B., Sagman, U., Auger, M., Demetrio, M., Dennis, J.W.: Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res. 51, 718-723 (1991
32. Couldrey, C., Green, J.E.: Metastases: The glycan connection. Breast Cancer Res. 2, 321-323 (2000 (Pubitemid 32223613)
33. Yamashita, K., Tachibana, Y., Ohkura, T., Kobata, A.: Enzymatic basis for the structural changes of asparagine-linked sugar chains of membrane glycoproteins of baby hamster kidney cells induced by polyoma transformation. J. Biol. Chem. 260, 3963-3969 (1985 (Pubitemid 15096459)
34. Dennis, J.W., Kosh, K., Bryce, D.M., Breitman, M.L.: Oncogenes conferring metastatic potential induce increased branching of Asn-linked oligosaccharides in rat2 fibroblasts. Oncogene 4, 853-860 (1989 (Pubitemid 19176972)
35. Astronomo, R.D., Burton, D.R.: Carbohydrate vaccines: Developing sweet solutions to sticky situations? Nat. Rev. Drug Discov. 9, 308-324 (2010
36. Helling, F., Shang, A., Calves, M., Zhang, S., Ren, S., Yu, R.K., Oettgen, H.F., Livingston, P.O.: GD3 vaccines for melanoma: Superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res. 54, 197-203 (1994
37. Plante, O.J., Palmacci, E.R., Seeberger, P.H.: Automated solidphase synthesis of oligosaccharides. Science 291, 1523-1527 (2001
38. Zhang, Z., Ollmann, I.R., Ye, X.S., Wischnat, R., Baasov, T., Wong, C.H.: Programmable one-pot oligosaccharide synthesis. J. Am. Chem. Soc. 121, 734-753 (1999
39. Huang, X., Huang, L., Wang, H., Ye, X.S.: Iterative one-pot synthesis of oligosaccharides. Angew. Chem. Int. Ed. 43, 5221- 5224 (2004 (Pubitemid 39382546)
40. Morel, P.A., Turner, M.S.: Designing the optimal vaccine: The importance of cytokines and dendritic cells. Open Vaccine J. 3, 7- 17 (2010
41. Hochweller, K., Anderton, S.M.: Kinetics of costimulatory molecule expression by T cells and dendritic cells during the induction of tolerance versus immunity in vivo. Eur. J. Immunol. 35, 1086-1096 (2005 (Pubitemid 40542215)
42. Flinsenberg, T.W.H., Compeer, E.B., Boelens, J.J., Boes, M.: Antigen cross-presentation: Extending recent laboratory findings to therapeutic intervention. Clin. Exp. Immunol. 165, 8-18 (2011
43. Cyster, J.G.: Chemokines and cell migration in secondary lymphoid organs. Science 286, 2098-2102 (1999 (Pubitemid 129516279)
44. Shuptrine, C.W., Surana, R., Weiner, L.M.: Monoclonal antibodies for the treatment of cancer. Semin. Cancer Biol. 22, 3-13 (2012
45. Dunkelberger, J.R., Song, W.C.: Complement and its role in innate and adaptive immune responses. Cell Res. 20, 34-50 (2010
46. Zipfel, P.F., Skerka, C.: Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9, 729-740 (2009
47. Ferris, R.L., Jaffee, E.M., Ferrone, S.: Tumor antigen-targeted, monoclonal antibody-based immunotherapy: Clinical response, cellular immunity, and immunoescape. J. Clin. Oncol. 28, 4390-4399 (2010
48. Kuduk, S.D., Schwarz, J.B., Chen, X.T., Glunz, P.W., Sames, D., Ragupathi, G., Livingston, P.O., Danishefsky, S.J.: Synthetic and immunological studies on clustered modes of mucin-related Tn and TF O-linked antigens: The preparation of a glycopeptidebased vaccine for clinical trials against prostate Cancer. J. Am. Chem. Soc. 120, 12474-12485 (1998 (Pubitemid 29003604)
49. Adluri, S., Helling, F., Ogata, S., Zhang, S., Itzkowitz, S.H., Lloyd, K.O., Livingston, P.O.: Immunogenicity of synthetic TFKLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol. Immunother. 41, 185-192 (1995
50. Fung, P.Y., Madej, M., Koganty, R.R., Longenecker, B.M.: Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res. 50, 4308-4314 (1990 (Pubitemid 20225670)
51. Livingston, P.O.: Approaches to augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol. Rev. 145, 147- 166 (1995
52. Helling, F., Zhang, S., Shang, A., Adluri, S., Calves, M., Koganty, R., Longenecker, B.M., Yao, T.J., Oettgen, H.F., Livingston, P.O.: GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 55, 2783-2788 (1995
53. Gilewski, T., Ragupathi, G., Bhuta, S., Williams, L.J., Musselli, C., Zhang, X.F., Bornmann, W.G., Spassova, M., Bencsath, K.P., Panageas, K.S., Chin, J., Hudis, C.A., Norton, L., Houghton, A.N., Livingston, P.O., Danishefsky, S.J.: Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: A phase I trial. Proc. Natl. Acad. Sci. USA 98, 3270-3275 (2001 (Pubitemid 32220835)
54. Ragupathi, G., Slovin, S.F., Adluri, S., Sames, D., Kim, I.J., Kim, H.M., Spassova, M., Bornmann, W.G., Lloyd, K.O., Scher, H.I., Livingston, P.O., Danishefsky, S.J.: A fully synthetic globo H carbohydrate vaccine induces a focused humoral response in prostate cancer patients: A proof of principle. Angew. Chem. Int. Ed. 38, 563-566 (1999 (Pubitemid 29095523)
55. Slovin, S.F., Ragupathi, G., Adluri, S., Ungers, G., Terry, K., Kim, S., Spassova, M., Bornmann, W.G., Fazzari, M., Dantis, L., Olkiewicz, K., Lloyd, K.O., Livingston, P.O., Danishefsky, S.J., Scher, H.I.: Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc. Natl. Acad. Sci. USA 96, 5710-5715 (1999 (Pubitemid 29234683)
56. Eggermont, A.M.M.: Therapeutic vaccines in solid tumours: Can they be harmful? Eur. J. Cancer. 45, 2087-2090 (2009
57. Holmberg, L.A., Sandmaier, B.M.: Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev. Vaccines 3, 655-663 (2004 (Pubitemid 39576752)
58. Slovin, S.F., Keding, S.J., Ragupathi, G.: Carbohydrate vaccines as immunotherapy for cancer. Immunol. Cell Biol. 83, 418-428 (2005 (Pubitemid 41044620)
59. Hollingsworth, M.A., Swanson, B.J.: Mucins in cancer: Protection and control of the cell surface. Nat. Rev. Cancer 4, 45-60 (2004 (Pubitemid 38082153)
60. Zhang, S., Walberg, L.A., Ogata, S., Itzkowitz, S.H., Koganty, R.R., Reddish, M., Gandhi, S.S., Longenecker, B.M., Lloyd, K.O., Livingston, P.O.: Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res. 55, 3364-3368 (1995
61. Slovin, S.F., Ragupathi, G., Musselli, C., Fernandez, C., Diani, M., Verbel, D., Danishefsky, S., Livingston, P., Scher, H.I.: Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: Clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol. Immunother. 54, 694-702 (2005 (Pubitemid 40884166)
62. Kagan, E., Ragupathi, G., Yi, S.S., Reis, C.A., Gildersleeve, J., Kahne, D., Clausen, H., Danishefsky, S.J., Livingston, P.O.: Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn. Cancer Immunol. Immunother. 54, 424-430 (2005 (Pubitemid 40543682)
63. Kaiser, A., Gaidzik, N., Westerlind, U., Kowalczyk, D., Hobel, A., Schmitt, E., Kunz, H.: A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: Induction of a strong and highly selective immune response. Angew. Chem. Int. Ed. 48, 7551-7555 (2009
64. Gaidzik, N., Kaiser, A., Kowalczyk, D., Westerlind, U., Gerlitzki, B., Sinn, H.P., Schmitt, E., Kunz, H.: Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues. Angew. Chem. Int. Ed. 50, 9977-9981 (2011
65. Hoffmann-Roder, A., Kaiser, A., Wagner, S., Gaidzik, N., Kowalczyk, D., Westerlind, U., Gerlitzki, B., Schmitt, E., Kunz, H.: Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue. Angew. Chem. Int. Ed. 49, 8498-8503 (2010
66. Livingston, P.O.: The unfulfilled promise of melanoma vaccines. Clin. Cancer Res. 7, 1837-1838 (2001
67. Ragupathi, G., Cappello, S., Yi, S.S., Canter, D., Spassova, M., Bornmann, W.G., Danishefsky, S.J., Livingston, P.O.: Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. Vaccine 20, 1030-1038 (2002 (Pubitemid 34135937)
68. Ragupathi, G., Koide, F., Sathyan, N., Kagan, E., Spassova, M., Bornmann, W., Gregor, P., Reis, C.A., Clausen, H., Danishefsky, S.J., Livingston, P.O.: A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLHconjugate vaccine against epithelial cancers. Cancer Immunol. Immunother. 52, 608-616 (2003 (Pubitemid 37268193)
69. Barington, T., Gyhrs, A., Kristensen, K., Heilmann, C.: Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine. Infect Immun. 62, 9-14 (1994 (Pubitemid 24011933)
70. Peeters, C.C., Tenbergen-Meekes, A.M., Poolman, J.T., Beurret, M., Zegers, B.J., Rijkers, G.T.: Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun. 59, 3504-3510 (1991
71. Fattom, A., Cho, Y.H., Chu, C., Fuller, S., Fries, L., Naso, R.: Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine 17, 126-133 (1999 (Pubitemid 28494111)
72. Allen, J.R., Harris, C.R., Danishefsky, S.J.: Pursuit of optimal carbohydrate-based anticancer vaccines: Preparation of a multiantigenic unimolecular glycopeptide containing the Tn, MBr1, and Lewis(y) antigens. J. Am. Chem. Soc. 123, 1890-1897 (2001 (Pubitemid 32200007)
73. Ragupathi, G., Coltart, D.M., Williams, L.J., Koide, F., Kagan, E., Allen, J., Harris, C., Glunz, P.W., Livingston, P.O., Danishefsky, S.J.: On the power of chemical synthesis: Immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines. Proc. Natl. Acad. Sci. USA 99, 13699-13704 (2002 (Pubitemid 35215444)
74. Keding, S.J., Danishefsky, S.J.: Prospects for total synthesis: A vision for a totally synthetic vaccine targeting epithelial tumors. Proc. Natl. Acad. Sci. USA 101, 11937-11942 (2004 (Pubitemid 39145375)
75. Ragupathi, G., Koide, F., Livingston, P.O., Cho, Y.S., Endo, A., Wan, Q., Spassova, M.K., Keding, S.J., Allen, J., Ouerfelli, O., Wilson, R.M., Danishefsky, S.J.: Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: A synthetic route to anticancer vaccine candidates. J. Am. Chem. Soc. 128, 2715-2725 (2006 (Pubitemid 43327950)
76. McCool, T.L., Harding, C.V., Greenspan, N.S., Schreiber, J.R.: B- And T-cell immune responses to pneumococcal conjugate vaccines: Divergence between carrier- And polysaccharidespecific immunogenicity. Infect Immun. 67, 4862-4869 (1999 (Pubitemid 29400475)
77. Herzenberg, L.A., Tokuhisa, T.: Carrier-priming leads to haptenspecific suppression. Nature 285, 664-667 (1980
78. Buskas, T., Thompson, P., Boons, G.J.: Immunotherapy for cancer: Synthetic carbohydrate-based vaccines. Chem. Commun. 36, 5335-5349 (2009
79. Buskas, T., Li, Y., Boons, G.J.: The immunogenicity of the tumor-associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein. Chem. Eur. J. 10, 3517-3524 (2004
80. Kumagai, Y., Akira, S.: Identification and functions of patternrecognition receptors. J. Allergy Clin. Immunol. 125, 985-992 (2010
81. Mahnke, K., Schmitt, E., Bonifaz, L., Enk, A.H., Jonuleit, H.: Immature, but not inactive: The tolerogenic function of immature dendritic cells. Immunol. Cell Biol. 80, 477-483 (2002
82. Olive, C.: Pattern recognition receptors: Sentinels in innate immunity and targets of new vaccine adjuvants. Expert Rev. Vaccines 11, 237-256 (2012
83. He, L.Z., Crocker, A., Lee, J., Mendoza-Ramirez, J., Wang, X.T., Vitale, L.A., O'Neill, T., Petromilli, C., Zhang, H.F., Lopez, J., Rohrer, D., Keler, T., Clynes, R.: Antigenic targeting of the human mannose receptor induces tumor immunity. J. Immunol. 178, 6259-6267 (2007 (Pubitemid 46717409)
84. Keler, T., Ramakrishna, V., Fanger, M.W.: Mannose receptortargeted vaccines. Expert. Opin. Biol. Ther. 4, 1953-1962 (2004
85. Apostolopoulos, V., Pietersz, G.A., Loveland, B.E., Sandrin, M.S., McKenzie, I.F.: Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc. Natl. Acad. Sci. USA 92, 10128-10132 (1995
86. Apostolopoulos, V., Pietersz, G.A., Gordon, S., Martinez- Pomares, L., McKenzie, I.F.: Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur. J. Immunol. 30, 1714-1723 (2000 (Pubitemid 30342815)
87. Apostolopoulos, V., Pietersz, G.A., McKenzie, I.F.: Cellmediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 14, 930-938 (1996 (Pubitemid 26280936)
88. Apostolopoulos, V., Barnes, N., Pietersz, G.A., McKenzie, I.F.: Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine 18, 3174-3184 (2000 (Pubitemid 30348658)
89. Karanikas, V., Hwang, L.A., Pearson, J., Ong, C.S., Apostolopoulos, V., Vaughan, H., Xing, P.X., Jamieson, G., Pietersz, G., Tait, B., Broadbent, R., Thynne, G., McKenzie, I.F.: Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100, 2783-2792 (1997 (Pubitemid 28007547)
90. Alexander, J., Sidney, J., Southwood, S., Ruppert, J., Oseroff, C., Maewal, A., Snoke, K., Serra, H.M., Kubo, R.T., Sette, A., et al.: Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1, 751-761 (1994
91. Alexander, J., Del Guercio, M.F., Maewal, A., Qiao, L., Fikes, J., Chesnut, R.W., Paulson, J., Bundle, D.R., DeFrees, S., Sette, A.: Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J. Immunol. 164, 1625-1633 (2000 (Pubitemid 30067283)
92. Martinez-Kinader, B., Lipford, G.B., Wagner, H., Heeg, K.: Sensitization of MHC class I-restricted T cells to exogenous proteins: Evidence for an alternative class I-restricted antigen presentation pathway. Immunology 86, 287-295 (1995
93. Metzger, J., Jung, G., Bessler, W.G., Hoffmann, P., Strecker, M., Lieberknecht, A., Schmidt, U.: Lipopeptides containing 2-(palmitoylamino)-6,7- bis(palmitoyloxy) heptanoic acid: Synthesis, stereospecific stimulation of B-lymphocytes and macrophages, and adjuvanticity in vivo and in vitro. J. Med. Chem. 34, 1969-1974 (1991
94. Spohn, R., Buwitt-Beckmann, U., Brock, R., Jung, G., Ulmer, A.J., Wiesmuller, K.H.: Synthetic lipopeptide adjuvants and Tolllike receptor 2-structure-activity relationships. Vaccine 22, 2494- 2499 (2004 (Pubitemid 38757349)
95. Toyokuni, T., Dean, B., Cai, S., Boivin, D., Hakomori, S., Singhal, A.K.: Synthetic vaccines: Synthesis of a dimeric Tn antigen-lipopeptide conjugate that elicits immune responses against Tn-expressing glycoproteins. J. Am. Chem. Soc. 116, 395-396 (1994
96. Kudryashov, V., Glunz, P.W., Williams, L.J., Hintermann, S., Danishefsky, S.J., Lloyd, K.O.: Toward optimized carbohydratebased anticancer vaccines: Epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice. Proc. Natl. Acad. Sci. USA 98, 3264-3269 (2001 (Pubitemid 32220834)
97. Cai, H., Huang, Z.H., Shi, L., Zhao, Y.F., Kunz, H., Li, Y.M.: Towards a fully synthetic MUC1-based anticancer vaccine: Efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry. Chem. Eur. J. 17, 6396- 6406 (2011
98. Casella, C.R., Mitchell, T.C.: Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol. Life Sci. 65, 3231-3240 (2008
99. Zhang, Y., Gaekwad, J., Wolfert, M.A., Boons, G.J.: Modulation of innate immune responses with synthetic lipid A derivatives. J. Am. Chem. Soc. 129, 5200-5216 (2007 (Pubitemid 46651398)
100. Wang, Q., Zhou, Z., Tang, S., Guo, Z.: Carbohydratemonophosphoryl lipid a conjugates are fully synthetic selfadjuvanting cancer vaccines eliciting robust immune responses in the mouse. ACS Chem. Biol. 7, 235-240 (2012
101. Bay, S., Lo-Man, R., Osinaga, E., Nakada, H., Leclerc, C., Cantacuzene, D.: Preparation of a multiple antigen glycopeptide (MAG) carrying the Tn antigen. A possible approach to a synthetic carbohydrate vaccine. J. Pept. Res. 49, 620-625 (1997 (Pubitemid 27335008)
102. Lo-Man, R., Bay, S., Vichier-Guerre, S., Deriaud, E., Cantacuzene, D., Leclerc, C.: A fully synthetic immunogen carrying a carcinomaassociated carbohydrate for active specific immunotherapy. Cancer Res. 59, 1520-1524 (1999 (Pubitemid 29160120)
103. Lo-Man, R., Vichier-Guerre, S., Bay, S., Deriaud, E., Cantacuzene, D., Leclerc, C.: Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope. J. Immunol. 166, 2849-2854 (2001 (Pubitemid 32173527)
104. Lo-Man, R., Vichier-Guerre, S., Perraut, R., Deriaud, E., Huteau, V., BenMohamed, L., Diop, O.M., Livingston, P.O., Bay, S., Leclerc, C.: A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates. Cancer Res. 64, 4987-4994 (2004 (Pubitemid 38924547)
105. Grigalevicius, S., Chierici, S., Renaudet, O., Lo-Man, R., Deriaud, E., Leclerc, C., Dumy, P.: Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered Tn antigen as synthetic anticancer vaccines. Bioconjug. Chem. 16, 1149-1159 (2005 (Pubitemid 41368116)
106. Dziadek, S., Hobel, A., Schmitt, E., Kunz, H.: A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response. Angew. Chem. Int. Ed. 44, 7630-7635 (2005 (Pubitemid 41713731)
107. Cremer, G.A., Bureaud, N., Piller, V., Kunz, H., Piller, F., Delmas, A.F.: Synthesis and biological evaluation of a multiantigenic Tn/TFcontaining glycopeptide mimic of the tumor-related MUC1 glycoprotein. ChemMedChem. 1, 965-968 (2006 (Pubitemid 44448795)
108. Buskas, T., Ingale, S., Boons, G.J.: Towards a fully synthetic carbohydrate-based anticancer vaccine: Synthesis and immunological evaluation of a lipidated glycopeptide containing the tumorassociated tn antigen. Angew. Chem. Int. Ed. 44, 5985-5988 (2005 (Pubitemid 41345916)
109. Ingale, S., Buskas, T., Boons, G.J.: Synthesis of glyco(lipo)peptides by liposome-mediated native chemical ligation. Org. Lett. 8, 5785-5788 (2006
110. Ingale, S., Wolfert, M.A., Gaekwad, J., Buskas, T., Boons, G.J.: Robust immune responses elicited by a fully synthetic threecomponent vaccine. Nat. Chem. Biol. 3, 663-667 (2007 (Pubitemid 47417705)
111. Lakshminarayanan, V., Thompson, P., Wolfert, M.A., Buskas, T., Bradley, J.M., Pathangey, L.B., Madsen, C.S., Cohen, P.A., Gendler, S.J., Boons, G.J.: Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc. Natl. Acad. Sci. USA 109, 261-266 (2012
112. Ingale, S., Wolfert, M.A., Buskas, T., Boons, G.J.: Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors. ChemBioChem. 10, 455-463 (2009
113. Bettahi, I., Dasgupta, G., Renaudet, O., Chentoufi, A.A., Zhang, X., Carpenter, D., Yoon, S., Dumy, P., BenMohamed, L.: Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes. Cancer Immunol. Immunother. 58, 187-200 (2009
114. Abdel-Motal, U., Wang, S., Lu, S., Wigglesworth, K., Galili, U.: Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes. J. Virol. 80, 6943-6951 (2006 (Pubitemid 44025193)
115. Abdel-Motal, U.M., Guay, H.M., Wigglesworth, K., Welsh, R.M., Galili, U.: Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells. J. Virol. 81, 9131-9141 (2007 (Pubitemid 47311456)
116. Sarkar, S., Lombardo, S.A., Herner, D.N., Talan, R.S., Wall, K.A., Sucheck, S.J.: Synthesis of a single-molecule L- rhamnose-containing three-component vaccine and evaluation of antigenicity in the presence of anti-L-rhamnose antibodies. J. Am. Chem. Soc. 132, 17236-17246 (2010
117. Tzianabos, A.O., Onderdonk, A.B., Rosner, B., Cisneros, R.L., Kasper, D.L.: Structural features of polysaccharides that induce intra-abdominal abscesses. Science 262, 416-419 (1993 (Pubitemid 23353382)
118. Mazmanian, S.K., Kasper, D.L.: The love-hate relationship between bacterial polysaccharides and the host immune system. Nat. Rev. Immunol. 6, 849-858 (2006 (Pubitemid 44631653)
119. Cobb, B.A., Wang, Q., Tzianabos, A.O., Kasper, D.L.: Polysaccharide processing and presentation by the MHCII pathway. Cell 117, 677-687 (2004 (Pubitemid 38692532)
120. Duan, J., Avci, F.Y., Kasper, D.L.: Microbial carbohydrate depolymerization by antigen-presenting cells: Deamination prior to presentation by the MHCII pathway. Proc. Natl. Acad. Sci. USA 105, 5183-5188 (2008 (Pubitemid 351738531)
121. De Silva, R.A., Wang, Q., Chidley, T., Appulage, D.K., Andreana, P.R.: Immunological response from an entirely carbohydrate antigen: Design of synthetic vaccines based on TñPS A1 Conjugates. J. Am. Chem. Soc. 131, 9622-9623 (2009
122. De Silva, R., Appulage, D., Pietraszkiewicz, H., Bobbitt, K., Media, J., Shaw, J., Valeriote, F., Andreana, P.: The entirely carbohydrate immunogen Tn-PS A1 induces a cancer cell selective immune response and cytokine IL-17. Cancer Immunol. Immunother. 61, 581-585 (2012
123. Krishnamachari, Y., Geary, S.M., Lemke, C.D., Salem, A.K.: Nanoparticle delivery systems in cancer vaccines. Pharm. Res. 28, 215-236 (2011
124. Ojeda, R., de Paz, J.L., Barrientos, A.G., Martin-Lomas, M., Penades, S.: Preparation of multifunctional glyconanoparticles as a platform for potential carbohydrate-based anticancer vaccines. Carbohydr. Res. 342, 448-459 (2007 (Pubitemid 46161419)
125. Dube, D.H., Bertozzi, C.R.: Metabolic oligosaccharide engineering as a tool for glycobiology. Curr. Opin. Chem. Biol. 7, 616- 625 (2003 (Pubitemid 37315799)
126. Lemieux, G.A., Bertozzi, C.R.: Modulating cell surface immunoreactivity by metabolic induction of unnatural carbohydrate antigens. Chem. Biol. 8, 265-275 (2001 (Pubitemid 32296116)
127. Liu, T., Guo, Z., Yang, Q., Sad, S., Jennings, H.J.: Biochemical engineering of surface alpha 2-8 polysialic acid for immunotargeting tumor cells. J. Biol. Chem. 275, 32832-32836 (2000
128. Zou, W., Borrelli, S., Gilbert, M., Liu, T., Pon, R.A., Jennings, H.J.: Bioengineering of surface GD3 ganglioside for immunotargeting human melanoma cells. J. Biol. Chem. 279, 25390-25399 (2004 (Pubitemid 38756796)
129. Guo, Z., Wang, Q.: Recent development in carbohydrate-based cancer vaccines. Curr. Opin. Chem. Biol. 13, 608-617 (2009
130. Pan, Y., Chefalo, P., Nagy, N., Harding, C., Guo, Z.: Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines. J. Med. Chem. 48, 875-883 (2005 (Pubitemid 40209110)
131. Chefalo, P., Pan, Y., Nagy, N., Guo, Z., Harding, C.V.: Efficient metabolic engineering of GM3 on tumor cells by N-phenylacetyl- D-mannosamine. Biochemistry 45, 3733-3739 (2006
132. Wu, J., Guo, Z.: Improving the antigenicity of sTn antigen by modification of its sialic acid residue for development of glycoconjugate cancer vaccines. Bioconjug. Chem. 17, 1537-1544 (2006 (Pubitemid 44851500)
133. Wang, Q., Ekanayaka, S.A., Wu, J., Zhang, J., Guo, Z.: Synthetic and immunological studies of 5′-N-phenylacetyl sTn to develop carbohydrate-based cancer vaccines and to explore the impacts of linkage between carbohydrate antigens and carrier proteins. Bioconjug. Chem. 19, 2060-2067 (2008
134. Wang, Q., Guo, Z.: Synthetic and immunological studies of sTn derivatives carrying 5-N-(p-Substituted Phenylacetyl)sialic acid for the development of effective cancer vaccines. ACS Med. Chem. Lett. 2, 373-378 (2011
135. Jennings, H.J., Gamian, A., Ashton, F.E.: N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis. J. Exp. Med. 165, 1207-1211 (1987 (Pubitemid 17064516)
136. Pon, R.A., Lussier, M., Yang, Q.L., Jennings, H.J.: NPropionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis. J. Exp. Med. 185, 1929-1938 (1997 (Pubitemid 27247079)
137. Krug, L.M., Ragupathi, G., Ng, K.K., Hood, C., Jennings, H.J., Guo, Z., Kris, M.G., Miller, V., Pizzo, B., Tyson, L., Baez, V., Livingston, P.O.: Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin. Clin. Cancer Res. 10, 916-923 (2004 (Pubitemid 38198890)
138. Krug, L.M., Ragupathi, G., Hood, C., George, C., Hong, F., Shen, R., Abrey, L., Jennings, H.J., Kris, M.G., Livingston, P.O.: Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci. Cancer Immunol. Immunother. 61, 9-18 (2012
139. Ragupathi, G., Meyers, M., Adluri, S., Howard, L., Musselli, C., Livingston, P.O.: Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int. J. Cancer 85, 659-666 (2000 (Pubitemid 30080479)
140. Ragupathi, G., Livingston, P.O., Hood, C., Gathuru, J., Krown, S.E., Chapman, P.B., Wolchok, J.D., Williams, L.J., Oldfield, R.C., Hwu, W.J.: Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactonekeyhole limpet hemocyanin conjugate vaccine plus
141. Wu, X., Lipinski, T., Paszkiewicz, E., Bundle, D.R.: Synthesis and immunochemical characterization of S-linked glycoconjugate vaccines against Candida albicans. Chem. Eur. J. 14, 6474-6482 (2008
142. Bundle, D.R., Rich, J.R., Jacques, S., Yu, H.N., Nitz,M., Ling, C.C.: Thiooligosaccharide conjugate vaccines evoke antibodies specific for native antigens. Angew. Chem. Int. Ed. 44, 7725-7729 (2005 (Pubitemid 41759536)
143. Rich, J.R., Bundle, D.R.: S-linked ganglioside analogues for use in conjugate vaccines. Org. Lett. 6, 897-900 (2004 (Pubitemid 38402656)
144. Rich, J.R., Wakarchuk, W.W., Bundle, D.R.: Chemical and chemoenzymatic synthesis of S-linked ganglioside analogues and their protein conjugates for use as immunogens. Chem. Eur. J. 12, 845-858 (2006 (Pubitemid 43099289)
145. Mersch, C., Wagner, S., Hoffmann-Roeder, A.: Synthesis of fluorinated analogues of tumor-associated carbohydrate and glycopeptide antigens. Synlett. 13, 2167-2171 (2009
146. Wagner, S., Mersch, C., Hoffmann-Röder, A.: Fluorinated glycosyl amino acids for mucin-like glycopeptide antigen analogues. Chem. Eur. J. 16, 7319-7330 (2010
147. Johannes, M., Oberbillig, T., Hoffmann-Roder, A.: Synthesis of fluorinated Thomsen-Friedenreich antigens: Direct deoxyfluorination of alphaGalNAc-threonine tert-butyl esters. Org. Biomol. Chem. 9, 5541-5546 (2011
148. Hoffmann-Roder, A., Johannes, M.: Synthesis of a MUC1- glycopeptide-BSA conjugate vaccine bearing the 3′-deoxy-3′- fluoro-Thomsen- Friedenreich antigen. Chem. Commun. 47, 9903-9905 (2011
149. Sahabuddin, S., Chang, T.C., Lin, C.C., Jan, F.D., Hsiao, H.Y., Huang, K.T., Chen, J.H., Horng, J.C., Ho, J.A., Lin, C.C.: Synthesis of N-modified sTn analogs and evaluation of their immunogenicities by microarray-based immunoassay. Tetrahedron 66, 7510-7519 (2010
150. Yang, F., Zheng, X.J., Huo, C.X., Wang, Y., Zhang, Y., Ye, X.S.: Enhancement of the immunogenicity of synthetic carbohydrate vaccines by chemical modifications of STn antigen. ACS Chem. Biol. 6, 252-259 (2011
151. Huo, C.X., Ye, X.S.: Synthesis of S-linked tumor-associated carbohydrate antigen STn. J. Chin. Pharm. Sci. 6, 214-217 (2009)